HR Positive/ HER2 Negative Breast Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AstraZeneca, Atossa, Bayer, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Immunomedics, Merus, Novartis, Pharmacia

Las Vega (Nevada), United States //- "HR Positive/ HER2 Negative Breast Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the HR Positive/ HER2 Negative Breast Therapeutics Market.

The report provides a detailed description of the HR Positive/ HER2 Negative Breast drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the HR Positive/ HER2 Negative Breast Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

HR Positive/ HER2 Negative Breast Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing HR Positive/ HER2 Negative Breast therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HR Positive/ HER2 Negative Breast treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging HR Positive/ HER2 Negative Breast drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the HR Positive/ HER2 Negative Breast treatment market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the HR Positive/ HER2 Negative Breast Therapeutics Domain:
https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Delveinsight's Report Covers Emerging Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the HR Positive/ HER2 Negative Breast Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

HR Positive/ HER2 Negative Breast Therapeutics Analysis
Globally, about 50+ key pharma and biotech companies are working on 53+ pipeline drugs in the HR Positive/ HER2 Negative Breast Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Companies like Radius Pharmaceuticals, Immunomedics, and Roche Group are coming up with novel therapeutic approaches that can entirely change the treatment landscape of breast cancer. If launched, these emerging could potentially change the current treatment landscape of breast cancer.

HR Positive/ HER2 Negative Breast Companies in the Therapeutics Market Include:
AstraZeneca, Atossa Therapeutics, Bayer, Chia Tai Tianqing Pharmaceutical Group, CytomX Therapeutics, Daiichi Sankyo, Inc., Eagle Pharmaceuticals, Eisai, Eli Lilly, Immunomedics, Jiangsu HengRui Medicine, Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merck Sharp and Dohme Corp., Merus N.V., Novartis, Pfizer, Pharmacia, Radius Pharmaceuticals, Regor Therapeutics, Roche, Seagen Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Syndax Pharmaceuticals, Taizhou EOC Pharma, Tyme, Inc., Upjohn Company, and many others.

Emerging and Marketed HR Positive/ HER2 Negative Breast Therapies Covered in the Report Include:
• Afinitor (Everolimus): Novartis
• Arimidex (Anastrozole): AstraZeneca
• Aromasin (Exemestane): Pharmacia and Upjohn Company
• Camizestrant: AstraZeneca
• CX-2009: CytomX Therapeutics
• Dato-DXd: Daiichi Sankyo, Inc.
• EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals
• Elacestrant (RAD1901): Radius Pharmaceuticals
• Entinostat: Syndax Pharmaceuticals
• Eribulin Mesylate: Merck Sharp and Dohme Corp./Eisai
• Faslodex (Fulvestrant Injection): AstraZeneca
• Femara (Letrozole): Novartis Pharmaceuticals
• Ibrance (Palbociclib): Pfizer
• Ipatasertib (RG7440): Roche
• Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals
• Lynparza (olaparib): AstraZeneca Pharmaceuticals
• Pembrolizumab (MK-3475): Merck Sharp and Dohme
• PIQRAY (Alpelisib; BYL719) Novartis
• Piqray (Alpelisib; BYL719): Novartis
• Radium-223 dichloride: Bayer
• RGT-419B: Regor Therapeutics
• Sacituzumab Govitecan (IMMU-132): Immunomedics
• SHR6390: Jiangsu HengRui Medicine
• Verzenio (Abemaciclib): Eli Lilly
And many more

Get an in-depth Assessment of the Emerging Therapies and HR Positive/ HER2 Negative Breast Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Current Treatment Patterns
4. HR Positive/ HER2 Negative Breast - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Late-Stage Products (Phase-III)
7. HR Positive/ HER2 Negative Breast Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. HR Positive/ HER2 Negative Breast Discontinued Products
13. HR Positive/ HER2 Negative Breast Product Profiles
14. HR Positive/ HER2 Negative Breast Companies
15. HR Positive/ HER2 Negative Breast Drugs
16. Dormant and Discontinued Products
17. HR Positive/ HER2 Negative Breast Unmet Needs
18. HR Positive/ HER2 Negative Breast Future Perspectives
19. HR Positive/ HER2 Negative Breast Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.